Principal Scientist, Cancer Pharmacology, Translational Research

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Principal Scientist in the Cancer Pharmacology team within the Translational Research group, in the Biomedical Discovery Research Department, you will: Provide scientific and strategic leadership for RAS(ON) inhibitor programs by translating mechanistic insights in RAS biology into impactful pharmacology strategies and translational study plans. Lead, mentor, and develop a high-performing group of in vivo scientists, fostering scientific excellence, innovation, and cross-functional collaboration. Drive the design, execution, and interpretation of in vivo efficacy and PK/PD studies conducted internally and through external partners to advance oncology discovery and development programs. Partner closely with the cross-functional quantitative modeling group to provide biological insight, translational context, and critical evaluation supporting PK/PD modeling efforts. Influence portfolio progression through generation of high-impact data packages and contributions to regulatory submissions. Serve as the in vivo pharmacology expert on cross-functional project teams, partnering closely with colleagues in Chemistry, Discovery Biology, DMPK, and Toxicology to build cohesive preclinical data sets. Communicate scientific strategy, key findings, and program recommendations to cross-functional teams and senior leadership to drive informed decision making. Required Skills, Experience and Education: Ph.D. in Pharmacology or Cancer Biology, or a related scientific discipline with direct relevance to oncology drug development. 5+ years of relevant industry experience in oncology drug discovery and development. Demonstrated scientific leadership, strategic thinking, and problem-solving skills in advancing oncology drug discovery programs. Deep expertise in tumor biology, RAS signaling pathways, and translational oncology pharmacology. Extensive hands-on experience in the design, analysis, and interpretation of in vivo oncology studies and disease models. Strong understanding of translational PK/PD concepts and integration of efficacy, biomarker, and pharmacokinetic data to support translational hypotheses. Working knowledge of modeling approaches, including PBPK, QSP, and semi-mechanistic PK/PD frameworks. Proven track record of leading, mentoring, and developing scientific talent within collaborative, matrixed research environments. Excellent written and verbal communication skills with the ability to effectively communicate complex scientific concepts to both specialist and non-specialist audiences. Demonstrated track record of scientific innovation, productivity, and collaboration in a dynamic and fast-paced drug discovery environment. Preferred Skills: Experience with RAS-targeted therapies and diverse oncology therapeutic modalities, including small molecules, antibodies, and antibody-drug conjugates (ADCs). Strong theoretical understanding of the concepts, assumptions, and limitations associated with PK/PD and translational mathematical modeling. Experience contributing to IND-enabling activities and regulatory documentation is desirable. Demonstrated ability to influence scientific strategy and effectively operate within highly collaborative cross-functional teams. #LI